Novartis (NVS -2.3%) launches a late-stage trial of an Enbrel (AMGN -1.9%) biosimilar in...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS -2.3%) launches a late-stage trial of an Enbrel (AMGN -1.9%) biosimilar in patients with plaque-type psoriasis. The news adds to recent findings regarding the effectiveness of a cheaper "triple therapy" which reportedly replicates Enbrel at a fraction of the cost.